Fosmetpantotenate (RE-024), a phosphopantothenate replacement therapy for pantothenate kinase-associated neurodegeneration: Mechanism of action and efficacy in nonclinical models
Fig 3
Intracellular CoA concentrations in shRNA PanK2 knockdown human neuroblastoma cells following incubations with fosmetpantotenate.
Experiment in triplicate. One-way ANOVA with Dunnett’s post-hoc analysis; *** p ≤0.001 **** p≤0.0001. NS: not significant.